Pramipexole

Both selected formulations are labeled for Parkinson’s disease. IR is used in divided daily doses; ER is taken once daily. Titration balances motor response with sleepiness, orthostasis, hallucinations, and dyskinesia. Do not use an RLS evening regimen as a Parkinson’s regimen.

IR tablets are also labeled for moderate-to-severe primary RLS; ER tablets are not labeled for RLS. AASM’s 2025 recommendation suggests against standard pramipexole use in adults with RLS because long-term harms, particularly augmentation, change the benefit-risk balance. Selected patients may prioritize short-term symptom relief after discussion; approval does not establish routine first-line status. Other investigational/off-label indications are outside this reference.

With CrCl > 50 mL/min, start 0.125 mg three times daily. Increase no more often than every 5–7 days: the label’s study schedule progresses through 0.25, 0.5, 0.75, 1, 1.25, and 1.5 mg three times daily, maximum 4.5 mg/day. Maintenance response is individualized; higher doses can add adverse effects without additional benefit. When combined with levodopa, consider a clinician-directed levodopa reduction. May be taken with or without food.

These are full-label CrCl bands for Parkinson’s disease, not RLS. Slow titration and clinical follow-up remain necessary.

Start 0.375 mg once daily, then 0.75 mg daily; increase by 0.75 mg no more often than every 5–7 days to maximum 4.5 mg/day. Swallow whole—never split, chew, or crush. CrCl 30–50: initially 0.375 mg every OTHER day; after 1 week, careful response/tolerability assessment may permit daily dosing, then 0.375 mg increments no more often than weekly, maximum 2.25 mg/day. ER is not recommended with CrCl < 30 or hemodialysis. The warning section notes limited renal-study evidence; the explicit moderate-renal schedule is from section 2.2.

Start 0.125 mg once daily 2–3 hours before bedtime. If needed, increase every 4–7 days to 0.25 mg, then 0.5 mg nightly. The label finds no additional benefit at 0.75 mg beyond 0.5 mg. With CrCl 20–60 mL/min, extend each titration step to 14 days. The selected label does not establish a separate RLS regimen below CrCl 20 or for dialysis; do not extrapolate from Parkinson’s tables or prescribe ER as an equivalent RLS product.

For Parkinson’s disease, the ER label permits an overnight IR-to-ER switch at the same total daily dose with monitoring and possible adjustment; renal restrictions still apply. Significant interruption may require retitration. Both Parkinson’s labels describe tapering by 0.75 mg/day to a daily dose of 0.75 mg, then reducing by 0.375 mg/day; individual withdrawal symptoms require supervision. RLS trials discontinued doses up to 0.75 mg without taper, but abrupt stopping caused rebound symptoms and labels warn about dopamine-agonist withdrawal. Do not interpret trial methods as a universal self-directed stop plan.

Both selected U.S. labels list no contraindications. This does not remove renal restrictions, psychosis-related avoidance, or the need to assess suspected hypersensitivity and other serious reactions.

Neither selected U.S. label contains a boxed warning. Sleep attacks, compulsive behaviors, psychosis, renal accumulation, and withdrawal remain major counseling issues.

Nausea, dizziness, constipation, somnolence, hallucinations, and dyskinesia are reported, with frequencies depending on indication/stage and concomitant levodopa. Other postmarketing reactions include severe behavioral changes and withdrawal symptoms; spontaneous reports do not establish frequency. Significant overdose experience is limited and there is no known antidote. Obtain medical assessment with supportive care, fluids and ECG monitoring as indicated; dialysis removes a negligible amount. Do not undertake gastric procedures or medication reversal at home.

Cimetidine increases exposure by inhibiting renal tubular secretion; other cation-transport substrates/inhibitors and amantadine may reduce clearance. Assess adverse effects and dose selection, especially with kidney impairment. Alcohol and sedating medicines increase sleepiness/sleep-attack concerns. No universal interaction-based reduction ratio is supplied.

Antipsychotic dopamine antagonists and metoclopramide may diminish pramipexole efficacy and complicate Parkinson’s symptoms. Levodopa can add dyskinesia and often requires adjustment based on motor response; the combination is not automatically contraindicated. Pramipexole undergoes negligible metabolism, so labels do not predict a major CYP-inhibitor elimination interaction.

Human pregnancy data are inadequate; animal findings do not establish a safe pregnancy dose. No human milk/infant-effect data are available. Pramipexole suppresses prolactin and is expected to inhibit lactation; assess maternal treatment needs, breastfeeding benefits, and possible infant effects. RLS in pregnancy requires treatment-specific assessment rather than transplanting a nonpregnant adult regimen.

Pediatric safety/effectiveness is not established or evaluated by the selected labels, and no pediatric dose is supplied. Older adults clear pramipexole more slowly, largely reflecting renal function, and have greater hallucination risk. Assess cognition, sleepiness, falls, and kidney function instead of assuming age alone permits the usual maximum.

Use the distinct IR Parkinson’s, IR RLS, and ER kidney schedules above. Dialysis clearance is very low; no renal-dose shortcut is invented. Hepatic-impairment PK studies are lacking, but unchanged renal elimination makes a major hepatic elimination effect unlikely; this is not proof of safety in every liver disease or a validated hepatic-stage table.

Pramipexole has activity at dopamine D2-family receptors, with preferential D3 binding. The exact Parkinson’s and RLS therapeutic mechanisms are not completely defined; striatal dopamine-receptor stimulation is relevant to Parkinson’s motor benefit. The same dopaminergic actions contribute to behavioral, movement, and prolactin effects.

Oral bioavailability is greater than 90%; metabolism is minimal and approximately 90% is recovered in urine, almost all unchanged, with active tubular secretion. IR peak concentration occurs about 2 hours after dosing and terminal half-life is about 8 hours in younger adults and 12 hours in older volunteers. ER peak timing is about 6 hours, with steady state around 5 days versus roughly 2 days for IR. These label profiles support a monitored Parkinson’s switch, not use of ER for RLS or identical schedules in renal impairment.

Assess motor/RLS response, blood-pressure symptoms/falls, sleep attacks, cognition/hallucinations, compulsive urges, dyskinesia, posture, renal function, and new interacting medicines. Reassess after titration and during/after withdrawal. For clinically significant RLS, AASM advises regular iron studies including ferritin and transferrin saturation, and correction of exacerbating medicines/substances and untreated sleep apnea; those assessments do not replace individual drug selection.

Avoid driving until effects are known; report sleep attacks immediately and do not resume hazardous activity simply because a dose was lowered. Rise slowly, involve caregivers in monitoring compulsive urges/psychosis, and report worsening earlier-day or spreading RLS symptoms. Take the exact formulation, swallow ER intact, and contact the clinician after an interruption or before stopping. Seek urgent assessment for fever/rigidity/confusion during withdrawal or significant unexplained muscle pain/weakness.

Strides IR 0.125 mg is white/off-white circular marked P1; other IR strengths are marked P2–P6. Representative 90-count 0.125 mg bottle NDC 64380-746-05. Ingenus ER 0.375 mg is white/off-white round marked 0.375/P11; higher ER strengths P12–P17 include oval tablets. Representative 30-count 0.375 mg bottle NDC 50742-331-30. Other generic appearances differ; Mirapex/Mirapex ER names do not establish current branded availability.

Covered IR tablets: 0.125, 0.25, 0.5, 0.75, 1, and 1.5 mg. Covered ER tablets: 0.375, 0.75, 1.5, 2.25, 3, 3.75, and 4.5 mg. Label strengths are pramipexole dihydrochloride product strengths; do not substitute a non-U.S. base-equivalent strength or compounded formulation without separate review.

Store both selected products at 20–25°C, with 15–30°C excursions. Protect IR from light and ER from high humidity. Keep out of children’s reach and preserve ER tablets whole. No opened-bottle expiration or nonlabel storage condition is invented.